Ensysce Biosciences has received notice from The Nasdaq Stock Market, as described in a decision dated February 26, 2024, that the Company may continue its listing on The Nasdaq Capital Market tier with an extension to May 13, 2024 in order to demonstrate compliance with the equity requirement in Listing Rule 5550(b)(1).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ENSC:
- Ensysce Biosciences completes meeting with FDA for PF614-MPAR
- Ensysce Biosciences announces publication of clinical bioequivalence manuscript
- Ensysce Biosciences Secures Funding and Expands Shareholder Value
- Ensysce Biosciences announces exercise of warrants for $4.7M in gross proceeds
- Ensysce Biosciences selected to present at AAPM Meeting